Thioredoxin reductase 1, cytoplasmic
Description:
| Description |
|---|
|
Drug Relations:
|
arsenic trioxide
|
Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of apoptosis in NB4 human promyelocytic leukemia cells in vitro. Arsenic trioxide also causes damage or degradation of the fusion protein promyelocytic leukemia (PML) retinoic acid receptor (RAR)-alpha. | Bioactivity details | MOA |
|
|
auranofin
|
An oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. Its exact mechanism of action is unknown, but it is believed to act via immunological mechanisms and alteration of lysosomal enzyme activity. Its efficacy is slightly less than that of injected gold salts, but it is better tolerated, and side effects which occur are potentially less serious. | Bioactivity details | MOA | |
|
aurothioglucose
|
A thioglucose derivative used as an antirheumatic and experimentally to produce obesity in animals. | Bioactivity details | MOA | |
|
methylthioninium chloride
|
A compound consisting of dark green crystals or crystalline powder, having a bronze-like luster. Solutions in water or alcohol have a deep blue color. Methylene blue is used as a bacteriologic stain and as an indicator. It inhibits GUANYLATE CYCLASE, and has been used to treat cyanide poisoning and to lower levels of METHEMOGLOBIN. | Bioactivity details | MOA |
|
|
sodium aurothiomalate
|
A variable mixture of the mono- and disodium salts of gold thiomalic acid used mainly for its anti-inflammatory action in the treatment of rheumatoid arthritis. It is most effective in active progressive rheumatoid arthritis and of little or no value in the presence of extensive deformities or in the treatment of other forms of arthritis. | Bioactivity details | MOA |